Although CD19 CAR-T treatment has shown feasibility and potential efficacy in SSc, how to further improve CAR-T cell function, reduce adverse reactions, prolong the duration of efficacy, and develop it as a routine treatment for SSc are still key issues that need to be urgently addressed (55, 56). The gene discussed is CD19; the disease is systemic sclerosis.